One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer — HYPORTAdjuvant  

Breast Cancer Female Clinical Trial

Official title: HYPOfractionated Radiation Therapy Comparing a Standard Radiotherapy Schedule (Over Three Weeks) With a Novel One Week Schedule in Adjuvant Breast Cancer: An Open Label Randomised Controlled Study (HYPORT- Adjuvant)

Status Recruiting

Clinical Trial Summary

Background:Moderate three week hypofractionated adjuvant radiotherapy schedule is a standard care in breast cancers. A five day schedule has been demonstrated to be iso-toxic as a standard three week schedule. Recently studies have also demonstrated the safety and feasibility of simultaneous integrated boost in this setting. This randomized trial will investigate if a one-week course of hypofractionated breast radiotherapy is non-inferior to a three week course.

Aim: To determine if one-week schedule of adjuvant radiotherapy in breast cancer is non-inferior to a three week schedule.

Primary Objective: Locoregional Recurrence Rate (LRR) (Cumulative proportion of patients with locoregional recurrence) at 5 years

Secondary Objective:

1. Overall survival (OS) (Time from randomization to death)

2. Invasive Disease-free survival (iDFS) (Time from randomization to any invasive disease recurrence, death due to any cause or second invasive malignancy)

3. Late adverse events (AE)

4. Quality of Life (QoL)

Hypothesis:

1. 1 week schedule will be non-inferior to a three week schedule for Locoregional Recurrence Rate

2. 1 week schedule will be non-inferior to a three week schedule for OS

3. 1 week schedule will be not result in worse late adverse events as compared to 3 week schedule

4. Proportion of patients decrease in quality of life will not differ between the two arms at 12 months

Design: Open-label, parallel group, two arm, randomised, phase III, non-inferiority trial.

Population: Patients with breast cancer who need adjuvant radiotherapy after breast conservation or mastectomy.

Intervention: Patients will be randomized to 15 days or 5 days of radiotherapy to the whole breast or chest wall or reconstructed breast. Nodal radiation will be delivered as indicated. A simultaneous integrated boost (SIB) will be delivered to patients who need a tumor bed boost after breast cancer. The following dose schedules will be tested:

Control Group: 40 Gy in 15 fractions over 3 weeks (with SIB of 8 Gy)*

Test Group: 26 Gy in 5 fractions over 1 week (with SIB of 6 Gy).*

• Use of Sequential Boost is allowed in both arms if prespecified by the institution. If used dose is 12 Gy in 4 fractions in 1 week in both arms.

Outcomes and measures:

1. LRR : Cumulative proportion of patients with ipsilateral Locoregional Recurrence after treatment at 5 years .

2. OS: Time from randomization to the time of death due to any cause. Cumulative proportion reported at 5 years.

3. iDFS: Time from randomization to any disease recurrence, death due to any cause or second primary invasive cancer.Cumulative proportion reported at 5 years.

4. AE: Proportion of patients with late Grade 2 or more AE as defined by the CTCAE 5 criteria

5. QoL: Proportion of patients with a worse summary score in the EORTC QLQ C30 at 12 months post-treatment as compared to the baseline score.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms

• NCT number: NCT03788213
• Study type: Interventional
• Source: Tata Medical Center
• Contact: Sanjoy Chatterjee, FRCR
• Phone: 9038161825
• Email: sanjoy.chatterjee@tmckolkata.com
• Status: Recruiting
• Phase: N/A
• Start date: March 26, 2019
• Completion date: March 26, 2029